Replimune Group, Inc. SEC filings REPL
Replimune Group, Inc. has 657 filings in SEC EDGAR's recent list, going back to May 3, 2018. Its latest annual report, Form ARS, was filed on Jul 29, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Oct 28, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (results of operations). The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jul 29, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 20, 2025 | — |
| CORRESP | Letter to the SEC | Feb 10, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 27, 2025 | — |
| EFFECT | Filing | Aug 14, 2024 | — |
| CORRESP | Letter to the SEC | Aug 13, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 9, 2024 | — |
| EFFECT | Filing | Jul 22, 2024 | — |
| POSASR | Filing | May 16, 2024 | — |
| EFFECT | Filing | Jul 27, 2022 | — |
| CORRESP | Letter to the SEC | Jul 27, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 30, 2022 | — |
| CT ORDER | Filing | Aug 18, 2021 | — |
| EFFECT | Filing | Aug 26, 2020 | — |
| CORRESP | Letter to the SEC | Aug 25, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 13, 2020 | — |
| EFFECT | Filing | Aug 15, 2019 | — |
| CORRESP | Letter to the SEC | Aug 15, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2019 | — |
| CORRESP | Letter to the SEC | Aug 7, 2019 | — |
| PRER14A | Filing | Aug 7, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 6, 2019 | — |
| EFFECT | Filing | Jul 19, 2018 | — |
| CT ORDER | Filing | Jul 19, 2018 | — |
| CERT | Filing | Jul 19, 2018 | — |
| 8-A12B | Filing | Jul 17, 2018 | — |
| CORRESP | Letter to the SEC | Jul 17, 2018 | — |
| CORRESP | Letter to the SEC | Jul 17, 2018 | — |
| CORRESP | Letter to the SEC | Jul 10, 2018 | — |
| CORRESP | Letter to the SEC | Jun 29, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 28, 2018 | — |
| CORRESP | Letter to the SEC | Jun 26, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 25, 2018 | — |
| DRS/A | Filing | Jun 19, 2018 | — |
| DRSLTR | Filing | Jun 11, 2018 | — |
| DRS/A | Filing | Jun 11, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 8, 2018 | — |
| DRSLTR | Filing | May 3, 2018 | — |
| DRS | Filing | May 3, 2018 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- REPL (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- Woburn, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1737953
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.